The company that won the Technology Export Award in the technology export category is ▲ Hanmi Pharmaceutical, which developed the non-alcoholic steatohepatitis treatment’Epinopegdeutide’ ▲ Legochem Bioscience, which developed ADC candidate material and ADC platform ▲ Original technology of human hyaluronidase Olix, who developed the developed Alteogen dry and wet macular degeneration treatment’OLX301A’ and subretinal fibrosis and wet macular degeneration treatment’OLX301D’, was selected.
Epinofegdeutide (LAPSGLP/GCG), a non-alcoholic steatohepatitis drug developed by Hanmi Pharmaceutical, is a dual-acting treatment that simultaneously activates GLP-1, which helps suppress insulin secretion and appetite, and glucagon, which increases energy metabolism.
Non-alcoholic steatohepatitis is a field with high medical unsatisfied demand because all approved treatments so far are the first in the world to be approved as a non-alcoholic steatohepatitis treatment as a domestic global new drug to improve the health of humanity around the world. It is expected that it will not only contribute, but also significantly reduce the patient’s economic burden.
Last year, Hanmi Pharmaceutical received a down payment of 10 million dollars (about 11.9 billion won) confirmed by MSD, and up to 860 million dollars (about 1.272 trillion won) for phased clinical development, approval, and commercialization milestones. A technology export contract was signed on the condition of receiving several percent sales royalties.
The ADC developed by LegoChem Bioscience is an innovative treatment that combines the selectivity of an antibody and the powerful cancer cell killing function of a drug by conjugating an antibody and an anticancer drug with a linker. It accurately delivers the drug to cancer cells without damaging normal cells. It is a technology that can significantly reduce side effects compared to.
In April, we signed a contract for the transfer of original ADC technology worth $47.25 million (approximately 4963 billion won) with Iksuda Therapeutics in the UK. ) Signed an additional contract, and in October, it signed a technology export contract with China’s Cystone Pharmaceuticals for up to $363.5 million (about 400 billion won) related to ADC anticancer drug.
In December, a total of 4 technologies were exported last year, including a contract for a total of $294 million (approximately 3255 billion won) with Pixies on Cology of the United States, and a technology export contract related to ADC anticancer drugs with a Japanese pharmaceutical company (not public). It achieved a global technology transfer performance of about 1.5 trillion won.
The original human hyaluronidase technology (ALT-B4) developed by Alteogen is a platform technology that converts existing intravenous antibodies or protein drugs into easy-to-use formulations for subcutaneous injection. It is expected that this technology can dramatically improve the medication convenience for patients and significantly reduce the treatment cost per patient.
Meanwhile, in June 2020, Alteogen was awarded a contract fee of 16 million dollars (19.4 billion won) to the top 10 global pharmaceutical companies, and a total of 3.65 billion dollars (4,677.1 billion won) for technical fees according to the development stage such as clinical development, approval and sales of candidate substances. It has signed a contract for non-exclusive technology transfer of scale, and in January 2021, it has continued to achieve results by signing a total of 126.6 billion won in contract with India’s Inta Spamacetical, a global generic company.
OLX301A, a treatment for dry and wet macular degeneration (AMD) developed by Olix, and OLX301D, a treatment for subretinal fibrosis and wet macular degeneration, are candidates for ribonucleic acid (RNA) treatment for up to four eye diseases. .
In October of last year, Olyx, a French ophthalmology company specialized in TEA Open Innovation, and advance payment of 5.3 million euros (about 7.2 billion won), and future milestones of 16165 million euros (about 22 billion billion won), for a total of 16.695 million euros (about 2282 billion won). ) Signed a technology export contract.
Dry macular degeneration, a treatment disease for’OLX301A’, and retinal fibrosis, a treatment disease for’OLX301D’, currently do not have a cure.If Olix successfully develops a treatment, OLX301A and OLX301D are the first innovative new drugs for the disease. It is highly anticipated to become a’first-in-class’.